Sale of Organon facility in Oss may avert closure
February 15, 2011Manufacturing and Production Merck & Co, Netherlands, Oss
The fate of an Organon manufacturing and R&D facility in the Netherlands, currently under threat of closure by parent company …
R&D productivity worse than previously reported
February 15, 2011Manufacturing and Production, Research and Development, Sales and Marketing BIO, BMT, FDA, R&D
A new analysis of pharma’s R&D pipelines suggests the overall success rate for drugs moving from clinical trials to FDA …
Pharmaceutical manufacturing news in brief
February 15, 2011Manufacturing and Production Boehringer Ingelheim, DSM Biologics, Elan, Novasep
Irish drugmaker Elan has forged an alliance with Boehringer Ingelheim to develop and manufacture antibody-based therapeutics. Under the terms of …
Medivir and Janssen in dengue fever research alliance
February 14, 2011Research and Development Dengue fever, Medivir
Medivir, the speciality pharma company focused on infectious diseases, it to collaborate with Janssen on discovering and developing new medicines …
Germany’s Merck pledges emphasis on women executives
February 14, 2011Sales and Marketing Merck KGaA, Women in pharma, equality
Merck KGaA has set itself the goal of increasing its proportion of women managers over the next five years. The …
7 Wins for Pulsar!
February 11, 2011Medical Communications, Sales and Marketing
Pulsar have done very well of late and managed to bag 1 silver Rx award and 6 New York Rx …
Digital Pharma: AZ presses the case for social media in pharma
February 11, 2011Medical Communications AZ, AstraZeneca, Digital Pharma blog, FDA, social media
Seemingly fed up with waiting for the FDA’s delayed social media guidance, AstraZeneca has published details of its own feedback …
Shire thrives on specialist portfolio
February 11, 2011Sales and Marketing 2010 pharma results, ADHD, Shire, Vyvanse
Speciality pharma company Shire has posted sales growth of 16%, led by its ADHD treatment Vyvanse. Sales of Vyvanse rose …
Pierre Fabre loses chief executive
February 11, 2011Sales and Marketing Olivier Bohuon, Pierre Fabre, Smith & Nephew, appointment, medical devices, sales and marketing
Olivier Bohuon is leaving French pharma company Pierre Fabre after serving just five months as its chief executive. He will …
Cephalon in trouble over party spirit
February 11, 2011Medical Communications ABPI, ABPI Code of Practice, Cephalon, PMCPA, industry reputation
Cephalon has been criticised by UK authorities for bankrolling “excessive” hospitality at a conference in Lisbon.The company was cited by …
TBWA Paling Walters adds to management board
February 11, 2011Medical Communications Andy Hayley, Ed Shorthose, Steve Morris, TBWA/Paling Walters, appointment, medical communications
London-based advertising agency TBWA\ Paling Walters has promoted Steve Morris and Ed Shorthose to the roles of managing partners. They …
Lilly chief issues warning on UK reforms
February 11, 2011Research and Development, Sales and Marketing John Lechleiter, US health reforms, healthcare reform, lilly, patent box, value-based pricing
Lilly chief executive John Lechleiter has warned that two key UK initiatives could fall seriously short of encouraging investment in …
Innovation is being stifled – Lilly chief executive
February 10, 2011Research and Development, Sales and Marketing Economist 2011 Pharma Summit, US health reforms, healthcare costs, healthcare reform, lilly
Supporting medical innovation should be a fundamental requirement of healthcare reforms, but current public policies are failing to do this, …
Digital Pharma: This is how pharma is using digital
February 10, 2011Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Android, Digital Pharma blog, Facebook, Twitter, disease awareness campaigns, ipad, iphone, social media
Pharma’s use of digital tools, from mobile apps to online campaigns to social media channels, is increasing all the time …
Amarin expands US operations
February 10, 2011Sales and Marketing AMR101, Amarin, Paul Huff, high cholesterol
Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey. …
WHO wants narcolepsy link with swine flu vaccine investigated
February 10, 2011Research and Development, Sales and Marketing Finland Institute, GSK, GlaxoSmithKline, Pandemrix, narcolepsy, swine flu
The World Health Organisation has called for further investigation into GSK’s swine flu vaccine link to sleeping disorder narcolepsy, following …
Dr Mikael von Euler moves to Oncos Therapeutics
February 10, 2011Research and Development Dr Mikael von Euler, Oncos Therapeutics, appointment, research and development
Finnish biotech company Oncos Therapeutics has appointed Dr Mikael von Euler as chief medical officer. He has more than 20 …
Alliance concerned over NHS competition reforms
February 10, 2011Health and Social Care Bill, NHS, NHS Alliance, NHS reforms
The NHS Alliance has called on the Government to clarify major issues around the Health and Social Care Bill which …
Generics force Sanofi into standstill
February 9, 2011Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics
An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …
Shire bags senior research execs from GSK and Abbott
February 9, 2011Research and Development Dr Lawson Macartney, Dr Mario Saltarelli, Shire, appointment, recruitment, research and development
Shire has strengthened its speciality pharmaceuticals business with the appointment of senior research executives from GlaxoSmithKline and Abbott. Dr Lawson …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
